However, in an analysis comparing severe COVID-19 patients to those with neuro-COVID-19 (characterized by neurological complications detected upon hospitalization and confirmed through electrophysical and other assessment metrics), serum GFAP levels were elevated in both cohorts compared to controls [82]. The gene discussed is GFAP; the disease is COVID-19.